Skip to main content
ARVN
NASDAQ Life Sciences

Arvinas Q2 2026: Revenue Hits $249.7M, Net Income $169.4M, and Cash Runway Extended to H2 2028

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$8.43
Mkt Cap
$520.041M
52W Low
$6.055
52W High
$14.51
52W Position info
39% above low
Off High info
42% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

ARVN sits 39% above its 52-week low of $6.055.

Summary

Driven by the VEPPANU licensing deal, Arvinas reported Q2 2026 revenue of $249.7M and net income of $169.4M. Cash runway extends to H2 2028, and the company outlined multiple near-term clinical data milestones.


Key Events · Earnings and Guidance · ARVN

  • Q2 Revenue Surges to $249.7M

    Revenue jumped from $22.4M a year ago, primarily due to $62.5M from the Rigel license agreement, a $50M milestone payment for VEPPANU approval, and $112.6M from the Pfizer collaboration.

  • Net Income of $169.4M

    Arvinas swung to a $169.4M net profit from a $61.2M loss in Q2 2025, driven by the licensing revenue and lower R&D expenses.

  • Cash Runway Extended to H2 2028

    Cash, equivalents, and marketable securities totaled $567.9M as of June 30, 2026, down from $685.4M at year-end 2025, but sufficient to fund operations into the second half of 2028.

  • Three Phase 1 Data Readouts in Next 12 Months

    Arvinas plans to share clinical data from ARV-393 (BCL6 degrader), ARV-102 (LRRK2 degrader), and ARV-027 (polyQ-AR degrader) over the next year, with ARV-393 data expected at a medical congress in H2 2026.


Analysis · ARVN · Life Sciences

A strong quarter for Arvinas was fueled by the VEPPANU licensing deal with Rigel, which contributed $62.5M in license revenue and a $50M milestone payment. The company swung to a $169.4M net profit from a year-ago loss, and cash reserves of $567.9M now fund operations into the second half of 2028. The pipeline is advancing with three Phase 1 data readouts expected over the next 12 months and a new immuno-oncology trial starting this quarter. While this quarter marks a financial inflection point, the real value driver remains the clinical pipeline — investors will watch for the upcoming data catalysts.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ARVN was trading at $8.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $520M. The 52-week trading range was $6.06 to $14.51. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ARVN - Latest Insights

ARVN
Nov 03, 2026, 4:04 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $7.09
Real-time Price: $6.69 info
Change: -$0.400 (-6%) info
Market Cap: $436.13M info
ARVN
Nov 03, 2026, 8:09 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.06
Real-time Price: $6.69 info
Change: -$0.370 (-5%) info
Market Cap: $436.13M info
ARVN
Nov 03, 2026, 7:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $7.52
Real-time Price: $6.69 info
Change: -$0.830 (-11%) info
Market Cap: $436.13M info
ARVN
Oct 07, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $7.52
Real-time Price: $6.69 info
Change: -$0.830 (-11%) info
Market Cap: $436.13M info
ARVN
Sep 28, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $7.60
Real-time Price: $6.69 info
Change: -$0.910 (-12%) info
Market Cap: $436.13M info